#biocon

Biocon Skips India's Crowded Generic Semaglutide Market, Eyes Global Expansion

Biocon's incoming CEO said the company will prioritize Canada, Brazil, and the Middle East instead of India's saturated GLP-1 market with 40+ generic entrants.